Bharat Biotech was established in the year 1996 by Dr. Krishna M. Ella and Mrs. Suchitra K. Ella, with a vision to generate innovative technologies, along with a strong backbone of intellectual capital for the manufacturing of unique vaccines and biotherapeutics. Today, Bharat Biotech is a multidimensional biotechnology company specializing in product-oriented research and development leading to the manufacture of vaccines and biotherapeutics with global IPR’s associated to its products.
Adding on to its achievements, Bharat Biotech has launched a new vaccine against Japanese Encephalitis on Friday. This drug has been jointly developed by the three leading research organisations : National Institute of Virology, Indian Council of Medical Research and Bharat Biotech.
In appreciation for this great achievemnet, Ghulam Nabi Azad, Minister of Health and Family, said the launch of this vaccine “reaffirms the strength and empowerment of our joint research effort in the last three to four years.”
Japanese Encephalitis is a disease caused by the mosquito-borne Japanese encephalitis virus that can cause brain inflammation, seizures and paralysis. The Japanese encephalitis virus is a virus from the family Flaviviridae.
For about three years, two doses of the vaccine are supposed to be given to develop immunity against this disease.
This vaccine, developed in India, costs around Rs 70 per dose, which is costlier than those imported from China which cost between Rs 20-30. But, since the doses are administered free of cost by the Indian Government, cost is not a big issue. Rather, we should acknowledge the advancements in research which will make us independent and self-reliant, at least in cases of diseases which have such huge impact.
Further, besides the more certain and immediate availability, the efficacy of the vaccine, which has been developed based on an Indian strain of the virus, is also likely to be higher.
Adding on to its achievements, Bharat Biotech has launched a new vaccine against Japanese Encephalitis on Friday. This drug has been jointly developed by the three leading research organisations : National Institute of Virology, Indian Council of Medical Research and Bharat Biotech.
In appreciation for this great achievemnet, Ghulam Nabi Azad, Minister of Health and Family, said the launch of this vaccine “reaffirms the strength and empowerment of our joint research effort in the last three to four years.”
Japanese Encephalitis is a disease caused by the mosquito-borne Japanese encephalitis virus that can cause brain inflammation, seizures and paralysis. The Japanese encephalitis virus is a virus from the family Flaviviridae.
For about three years, two doses of the vaccine are supposed to be given to develop immunity against this disease.
This vaccine, developed in India, costs around Rs 70 per dose, which is costlier than those imported from China which cost between Rs 20-30. But, since the doses are administered free of cost by the Indian Government, cost is not a big issue. Rather, we should acknowledge the advancements in research which will make us independent and self-reliant, at least in cases of diseases which have such huge impact.
Further, besides the more certain and immediate availability, the efficacy of the vaccine, which has been developed based on an Indian strain of the virus, is also likely to be higher.
